These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 29454983)

  • 21. Recent developments in glycopeptide antibacterials.
    Barrett JF
    Curr Opin Investig Drugs; 2005 Aug; 6(8):781-90. PubMed ID: 16121684
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Oritavancin - a new semisynthetic lipoglycopeptide agent to tackle the challenge of resistant gram positive pathogens.
    Das B; Sarkar C; Schachter J
    Pak J Pharm Sci; 2013 Sep; 26(5):1045-55. PubMed ID: 24035967
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Biosynthesis of glycopeptides: prospects for improved antibacterials.
    Donadio S; Sosio M
    Curr Top Med Chem; 2008; 8(8):654-66. PubMed ID: 18473890
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Glycopeptide Hypersensitivity and Adverse Reactions.
    Huang V; Clayton NA; Welker KH
    Pharmacy (Basel); 2020 Apr; 8(2):. PubMed ID: 32326261
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Characterization of the in vitro activity of novel lipoglycopeptide antibiotics.
    Arhin FF; Belley A; McKay GA; Moeck G
    Curr Protoc Microbiol; 2010 Feb; Chapter 17():Unit17.1. PubMed ID: 20131224
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Biosynthesis, biotechnological production, and application of teicoplanin: current state and perspectives.
    Jung HM; Jeya M; Kim SY; Moon HJ; Kumar Singh R; Zhang YW; Lee JK
    Appl Microbiol Biotechnol; 2009 Sep; 84(3):417-28. PubMed ID: 19609520
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Chapter 18. Molecular genetic approaches to analyze glycopeptide biosynthesis.
    Wohlleben W; Stegmann E; Süssmuth RD
    Methods Enzymol; 2009; 458():459-86. PubMed ID: 19374994
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Production of hybrid glycopeptide antibiotics in vitro and in Streptomyces toyocaensis.
    Solenberg PJ; Matsushima P; Stack DR; Wilkie SC; Thompson RC; Baltz RH
    Chem Biol; 1997 Mar; 4(3):195-202. PubMed ID: 9115410
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-Acting Lipoglycopeptides Can Interfere With Vancomycin Therapeutic Drug Monitoring.
    Smelter DF; Trisler MJ; McCreary EK; Baker M; Copeland K; Dilworth TJ; Rose WE
    J Clin Pharmacol; 2022 Apr; 62(4):472-478. PubMed ID: 34564865
    [TBL] [Abstract][Full Text] [Related]  

  • 30. New insights into glycopeptide antibiotic binding to cell wall precursors using SPR and NMR spectroscopy.
    Treviño J; Bayón C; Ardá A; Marinelli F; Gandolfi R; Molinari F; Jimenez-Barbero J; Hernáiz MJ
    Chemistry; 2014 Jun; 20(24):7363-72. PubMed ID: 24805824
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lipoglycopeptide Antibacterial Agents in Gram-Positive Infections: A Comparative Review.
    Van Bambeke F
    Drugs; 2015 Dec; 75(18):2073-95. PubMed ID: 26603874
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Emergence of dalbavancin non-susceptible, vancomycin-intermediate Staphylococcus aureus (VISA) after treatment of MRSA central line-associated bloodstream infection with a dalbavancin- and vancomycin-containing regimen.
    Werth BJ; Jain R; Hahn A; Cummings L; Weaver T; Waalkes A; Sengupta D; Salipante SJ; Rakita RM; Butler-Wu SM
    Clin Microbiol Infect; 2018 Apr; 24(4):429.e1-429.e5. PubMed ID: 28782651
    [TBL] [Abstract][Full Text] [Related]  

  • 33. New Gram-Positive Agents: the Next Generation of Oxazolidinones and Lipoglycopeptides.
    Crotty MP; Krekel T; Burnham CA; Ritchie DJ
    J Clin Microbiol; 2016 Sep; 54(9):2225-32. PubMed ID: 26962092
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Glycopeptide antibiotic biosynthesis.
    Yim G; Thaker MN; Koteva K; Wright G
    J Antibiot (Tokyo); 2014 Jan; 67(1):31-41. PubMed ID: 24220108
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antibiotics for gram-positive bacterial infections: vancomycin, teicoplanin, quinupristin/dalfopristin, oxazolidinones, daptomycin, dalbavancin, and telavancin.
    Nailor MD; Sobel JD
    Infect Dis Clin North Am; 2009 Dec; 23(4):965-82, ix. PubMed ID: 19909893
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vitro stepwise selection of reduced susceptibility to lipoglycopeptides in enterococci.
    Arhin FF; Seguin DL; Belley A; Moeck G
    Diagn Microbiol Infect Dis; 2017 Oct; 89(2):168-171. PubMed ID: 28733126
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vitro antistaphylococcal activity of dalbavancin, a novel glycopeptide.
    Lopez S; Hackbarth C; Romanò G; Trias J; Jabes D; Goldstein BP
    J Antimicrob Chemother; 2005 Mar; 55 Suppl 2():ii21-4. PubMed ID: 15750033
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Glycopeptides and glycodepsipeptides in clinical development: a comparative review of their antibacterial spectrum, pharmacokinetics and clinical efficacy.
    Van Bambeke F
    Curr Opin Investig Drugs; 2006 Aug; 7(8):740-9. PubMed ID: 16955686
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Regulation of teicoplanin biosynthesis: refining the roles of tei cluster-situated regulatory genes.
    Yushchuk O; Horbal L; Ostash B; Marinelli F; Wohlleben W; Stegmann E; Fedorenko V
    Appl Microbiol Biotechnol; 2019 May; 103(10):4089-4102. PubMed ID: 30937499
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Glycopeptide Antibiotic Resistance Genes: Distribution and Function in the Producer Actinomycetes.
    Yushchuk O; Binda E; Marinelli F
    Front Microbiol; 2020; 11():1173. PubMed ID: 32655512
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.